Triple negative breast cancer (TNBC), which constitutes about 15 to 20% of the breast cancer cases, is characterized by the lack of expression for hormone receptors (estrogen receptor [ER-] and progesterone receptor [PR-]) and human epidermal growth factor receptor 2 (HER2) (1–3). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.